List of Tables
Novartis AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 20
Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 21
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 22
Novartis AG, Deals By Therapy Area, 2011 to YTD 2017 23
Novartis AG, Medical Devices Deals, 2011 to YTD 2017 25
Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 26
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 59
Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 61
Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 62
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 63
Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 64
Teva Pharma May Divest its Assets 65
Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 67
Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For US$43 Million 69
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 70
Novartis Acquires Global Patent Rights To Molecular Target From ARCA Biopharma 71
Sandoz To Acquire Marketing And Supplying Assets Of InterPharma 72
Perlara Raises USD7.4 Million in Venture Financing 73
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 74
ImaginAb Raises USD7.7 Million in Venture Financing 76
Rani Therapeutics Raises USD39 Million in Series D Financing 77
Homology Medicines Raises USD83.5 Million in Series B Financing 78
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 80
NeuroVia Raises USD14 Million in Series A Financing 82
E-scape Bio Raises Additional USD8 Million in Series A Financing 83
Anaeropharma Science Raises USD13.2 Million in Venture Financing 84
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 85
ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 87
Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 88
Cavion Raises USD26 Million in Series A Financing 89
Inflazome Raises USD17 Million in Series A Financing 90
Rox Medical Raises USD40 Million in Series E Financing 91
Annexon Biosciences Raises USD44 Million in Series B Financing 92
IFM Therapeutics Raises USD27 Million in Series A Financing Round 93
F2G Raises USD60 Million in Venture Financing 94
Blade Therapeutics Raises USD27 Million in Series B Financing 96
Caribou Biosciences Raises USD30 Million in Series B Financing Round 98
Ideaya Biosciences Raises USD46 Million in Series A Financing 100
Rani Therapeutics Raises Funds in Financing 102
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 104
Adicet Bio Raises USD51 Million in Series A Financing Round 105
C4 Therapeutics Raises USD73 Million in Series A Financing Round 106
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 107
Galera Therapeutics Raises USD37 Million in Series B Financing 109
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 110
Intellia Therapeutics Raises USD70 Million in Series B Financing 112
Merus Raises USD46.4 Million in First Tranche of Series C Financing 114
Encore Vision Raises USD2.5 Million in Series C Financing 116
E-scape Bio Raises USD55 Million in Series A Financing 117
Ra Pharma Raises USD58.5 Million in Series B Financing 118
Kanyos Bio Raises USD16 Million in Venture Financing 119
Arcus Biosciences Raises USD50 Million in Series A Financing 120
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 121
Innocrin Pharma Raises USD28 Million in Series D Financing 122
Nabriva Therapeutics Raises USD120 Million in Series B Financing 123
Caribou Biosciences Raises USD11 Million in Series A Financing 125
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 127
Neurovance Raises Additional USD5.5 Million in Venture Financing 128
Macrolide Pharma Raises USD22 Million in Series A Financing 129
Merganser Biotech Raises USD28 Million in Series A Financing 130
Vaxin Raises USD16 Million in Venture Financing 131
Surface Oncology Raises USD35 Million in Series A Financing 132
Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 134
Advanced Animal Diagnostics Raises USD15 Million in Series C Venture Financing 135
BioNano Genomics Raises USD53 Million in Series C Venture Financing 136
Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 138
Ziarco Raises USD33 Million in Series B Venture Financing 139
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 140
Quartet Medicine Raises USD17 Million in Series A Venture Financing 142
Innocrin Pharma Raises Funds through Venture Financing 143
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 144
Viamet Pharma Raises USD60 Million in Series D Venture Financing 146
Raze Therapeutics Raises USD24 Million in Series A Venture Financing 147
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 149
Neurovance Raises Additional USD4 Million in Venture Financing 150
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 151
Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 152
ImaginAb Raises US$21 Million In Series B Venture Financing 153
Anokion Raises US$37.5 Million In Series A Venture financing 154
Aerpio Therapeutics Raises Us$22 Million In Venture Financing 155
Spinifex Pharma Raises US$45 Million In Series C Financing 157
Alios BioPharma Raises US$41 Million In Series B Venture Financing 159
Thesan Pharma Raises US$49 Million In Series B Venture Financing 160
Covagen Raises US$50.3 Million In Series B Financing 161
Encore Vision Secures USD5 Million in Venture Funding 163
Aileron Therapeutics Raises US$30 Million In Series E Financing 164
Aerpio Therapeutics Raises US$9 Million In Extended Series A Financing 166
Merus Raises US$42 Million In Extended Series B Financing 168
Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 170
Akebia Therapeutics Raises US$41 Million In Series C Financing 172
Effector Therapeutics Raises US$45 Million In Series A Financing 173
Tokai Pharma Raises US$35.5 Million In Series E Financing 175
Neurovance Raises US$6 Million In Series A1 Financing 176
GenSight Biologics Raises US$41.6 Million In Series A Financing 178
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 180
CoStim Pharma Raises US$10 Million In Venture Financing 182
Aileron Raises US$12 Million In Extended Series D Financing 183
Bicycle Therapeutics Raises US$6 Million In Venture Financing 185
Galera Therapeutics Raises US$11 Million In Series A Financing 187
Ziarco Pharma Raises US$6 Million In First Tranche Of Series A financing 188
Thesan Pharma Raises Additional US$12 Million In Series A Financing 189
Qurient Raises US$4 Million In Venture Financing 190
Selexys Pharma Raises US$23 Million In Series A Financing 191
F2G Raises US$30 Million In Venture Financing 192
Aerpio Therapeutics Raises US$27 Million In Series A Financing 193
PharmAbcine Raises US$3.5 Million In Series B Financing 194
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 195
Celladon Raises Additional US$10 Million In Series D Financing 196
BioRelix Raises US$0.27 Million In Venture Financing 198
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 199
Akebia Therapeutics Secures Additional US$4.1 Million In Series B Financing 200
AMP Therapeutics Raises Funds Through Series A Financing 201
Aerpio Therapeutics Secures US$5 Million In Venture Financing 202
Selexys Pharma Secures Additional US$2.2 Million In Venture Financing 203
Tokai Pharma Raises US$23 Million In Series D3 Financing 204
Spinifex Pharma Secures An Additional US$6.5 Million In Series B Financing 205
Pulmatrix Secures US$14 Million In Series B1 Venture Financing 207
Sorbent Therapeutics Secures An Additional US$36 Million In Series B Venture Financing 208
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 209
ProCertus BioPharm Raises An Additional US$1.7 Million In Series A Venture Financing 211
Quro Science Secures US$1 Million In Venture Financing 212
Euthymics Bioscience Secures Additional US$4 Million In Series A Venture Financing 213
Viamet Pharma Secures Additional US$15 Million In Series B Financing 215
Samara Capital Partners Acquires Anti-Infective Brands from Novartis 216
Gamida Cell Raises USD40 Million in Private Financing 217
Ampersand Capital Partners and 1315 Capital Acquires Genoptix 219
dievini Hopp BioTech to Acquire Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 220
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 221
Camurus Exercises Option For Licensing Agreement With Novartis For Octreotide 222
Homology Medicines Enters into Agreement with Novartis 224
Novartis Enters into Agreement with University of California 225
Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 226
Cipla and Novartis May Enter into Co-Marketing Agreement 227
Oxford BioMedica Enters into Agreement with Novartis 228
Bristol-Myers Squibb Enters into Partnership with Novartis 229
Allergan Enters into Agreement with Novartis 230
Perthera Enters into Agreement with Novartis 231
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 232
Protagen Enters into Agreement with Novartis Pharma 234
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 235
Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 236
Cerulean Pharma Enters into Partnership with Novartis 237
Perlara Enters into Partnership with Novartis 238
Cure Forward Partners with Novartis Pharma 239
Novartis Expands its Agreement with Medicines for Malaria Venture 240
Novartis Pharma Enters into Agreement with Eisai 241
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 242
Cigna Enters into Contract with Novartis 243
MedinCell Enters into Agreement with Sandoz International 244
Radius Health Partners with Novartis Pharma for RAD1901 245
NeoBiocon Enters into Agreement with Novartis 246
Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 247
Amgen Expands its Co-Development Agreement with Novartis 248
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 249
Sosei Plans to Enter into Agreement with Novartis 250
Rani Therapeutics Enters into Agreement with Novartis 251
PaxVax Enters into Distribution Agreement with Novartis 252
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 253
Semma Therapeutics Enters into Agreement with Novartis 254
Novartis Enters into Co-Development Agreement with Department of Science & Technology 255
PeptiDream Expands Drug Discovery Agreement with Novartis 256
BioLineRx Enters into Agreement with Novartis Pharma 257
Rega Institute for Medical Research, Centre for Drug Design and Discovery, KRICT Enters into Partnership with Novartis 258
Fougera Pharma Enters into Co-Promotion Agreement with Women’s Choice Pharma for Veregen 259
Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 260
Novartis Enters into Co-Marketing Agreement with Pharmathen Pharma 261
Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 262
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 263
Amgen and Novartis Expands Partnership with Banner Alzheimer Institute 265
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 266
Servier Expands Agreement with Novartis 267
Cytovance Biologics Enters Into Co-Development Agreement With Selexys Pharma 268
Foundation Medicine Expands Co-Development Agreement With Novartis 269
Rovi Enters Into Agreement With Novartis Farma To Market Hirobriz Breezhaler And Ulunar Breezhaler 270
GigaGen Enters into Research Agreement with Novartis 271
Novartis Enters Into Distribution Agreement With WhanIn For Clozaril 272
Oxford BioMedica Enters into Agreement with Novartis 273
Handok Pharma Enters Into Co-Marketing Agreement With Novartis Korea For Onbrez Breezhaler 274
Novartis Institutes for BioMedical Research Enters into Co-Development Agreement with University of Cape Town 275
PeptiDream Expands Macrocylic Peptide Drug Discovery Agreement with Novartis 276
MorphoSys Expands Co-Development Agreement With Novartis For Therapeutic Antibodies 277
Idenix Pharma Amends Its Agreement With Novartis Pharma 279
Sandoz Enters Into Co-promotion Agreement With Nipro Pharma For Somatropin BS S.C. Injection 5mg/10mg [Sandoz] 280
AnaptysBio Enters Into Co-Development Agreement With Novartis 281
SomaLogic Enters Into Co-Development Agreement With Novartis 282
Hyundai Pharma Enters Into Co-Marketing Agreement With Novartis Korea 283
Sandoz Korea Enters Into Co-Promotion Agreement With Ildong Pharma 284
Sandoz Extends Co-Development Agreement With Nipro 285
Mendor Enters Into Co-Development Agreement With Novartis 286
Biovista Enters Into Research Collaboration With Novartis 287
NasVax Extends Its Research Agreement With Novartis 288
Duke Human Vaccine Institute Enters Into Research Agreement With Novartis Vaccines 289
InVivoScribe Technologies Enters Into An Agreement With Novartis 291
WhanIn Pharma Enters Into Co-Promotion Agreement With Sandoz 292
Zhejiang Huahai Pharma Enters Into Agreement With Novartis And Sandoz To Develop Medicines 293
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 294
Oncology Venture Enters into Option Agreement with Novartis Pharma to License Small Molecule Compound 295
Sandoz Enters into Licensing Agreement with Vectura 296
Sandoz Enters into Licensing Agreement with DURECT 297
Midatech Pharma Enters Into Licensing Agreement with Novartis 298
Novartis Pharma Exercises Option for Licensing Agreement with Conatus Pharma 299
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 300
Novartis Enters into Licensing Agreement with Celyad 301
Novartis Pharma Enters into Licensing Agreement with bluebird bio 302
Novartis Enters into Licensing Agreement with Parvus Therapeutics 303
Novartis Exercises Option for Licensing Agreement with Tribos 304
PureTech Enters into Licensing Agreement with Novartis 305
Sandoz International Enters into Licensing Agreement with DSM Sinochem Pharma 306
Novartis Enters into Licensing Agreement with Ligand Pharma 307
Sunovion Pharma Enters into Licensing Agreement with Novartis 308
Sandoz and Beximco Pharma Enter into Licensing Agreement with Medicines Patent Pool 309
Kyowa Hakko Kirin Enters into Licensing Agreement with Sandoz 310
Surface Oncology Enters into Licensing Agreement with Novartis 311
Novartis Enters into Licensing Agreement with Palobiofarma 312
Novartis Enters into Licensing Agreement with XOMA 313
Aveo Pharma Enters into Licensing Agreement with Novartis 314
Cytos Biotechnology Enters into License Agreement with Novartis 315
Caribou Biosciences Enters into Licensing Agreement with Novartis 316
Novartis Enters into Research and Licensing Agreement with Intellia Therapeutics 317
Novartis Enters into Licensing Agreement with Global Alliance for TB Drug Development for Tuberculosis Drugs 318
Ophthotech Amends Licensing Agreement with Novartis 319
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 321
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 323
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 325
Genmab Enters Into Licensing Agreement With Novartis For DuoBody Technology Platform 326
Vectura Group Enters Into Licensing Agreement With Sandoz For VR315 327
Cyon Therapeutics Enters into Licensing Agreement with Novartis 328
Novartis Enters into Licensing Agreement with Xencor 329
Novartis Enters into Licensing Agreement with Rhizen Pharma 330
Luc Therapeutics Enters into Licensing Agreement with Novartis 331
BioQuiddity Expands Licensing Agreement with Sandoz 332
PeptiDream Exercises Option for Licensing Agreement with Novartis 333
Apricus Expands Licensing Agreement with Hexal for Vitaros 334
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 335
Oxford BioMedica Enters into Licensing Agreement with Novartis for LentiVector 336
ImmunoGen Extends Licensing Agreement with Novartis 337
ProBioGen Enters into Lincencing Agreement with Novartis for GlymaxX ADCC Technology 338
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 339
Nuevolution Enters Into Licensing Agreement With Novartis 341
Taiwan Liposome Enters Into Licensing Agreement With Sandoz For AmBiL 342
Apricus Biosciences Expands Licensing Agreement With Hexal For Vitaros 343
Retrophin Enters Into Licensing Agreement With Novartis Pharma For Syntocinon Nasal Spray 344
ImmunoGen Enters Into Licensing Agreement With Novartis To Develop Anticancer Therapeutics 345
Novartis Enters Into Licensing Agreement With ImmunoGen 346
Novartis Enters Into Licensing Agreement With Regenerex For Facilitating Cell Therapy Platform 347
Ensemble Therapeutics Enters Into Licensing Agreement With Novartis To Develop Interleukin-17 Antagonists 348
Life Technologies Enters Into Licensing Agreement With Novartis 349
Novartis Enters Into Licensing Agreement With Biological E 350
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 351
GenSight Biologics Enters into Licensing Agreement with Novartis Pharma 352
Taisho Pharma Enters Into Licensing Agreement With Novartis Pharma For TS-071 353
Ziarco Pharma Enters Into Licensing Agreement With Pfizer 354
CoStim Pharma Enters into Licensing Agreement with Immutep 355
Novartis Enters Into Licensing Agreement With University of Pennsylvania For CART-19 356
Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations 358
Novartis Amends Licensing Agreement With AlphaVax 359
GenVec Extends Licensing And Research Agreement With Novartis 360
Cellectis Enters Into Licensing Agreement With Novartis 361
ChemDiv Research Institute Enters Into Licensing Agreement With Novartis Institute for Tropical Diseases For Tuberculosis 362
Alentia Biotech Enters Into Licensing Agreement With Novartis 363
FAES Farma Enters Into Licensing Agreement With Novartis Farmaceutica For Hirobriz and Breezhaler 364
GW Pharma Terminates License Agreement With Novartis Pharma 365
Nerviano Medical Sciences Enters Into Licensing Agreement With Novartis 366
Acino Holding Enters Into Licensing Agreement With Novartis For Rivastigmine 367
Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research 368
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 369
Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 370
Akcea Therapeutics Raises USD50 Million in Private Placement of Shares 372
Aerpio Pharma Raises USD40 Million in Private Placement of Shares 373
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 374
Perlara Raises Funds in Equity Financing 375
Intellia Therapeutics Raises USD70 Million in Private Placement of Series B Preferred Stock 376
Anokion to Raise USD16 Million in Private Placement of Shares 378
Aduro BioTech Raises USD25 Million in Private Placement Shares 379
Tokai Pharma Raises USD0.71 Million in Public Offering of Shares 380
Caribou Biosciences Raises Funds through Private Placement of Shares 381
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 382
Intercell Completes Private Placement Of Shares For US$19.8 Million 384
Idenix Pharma Completes Private Placement For US$5 Million 385
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 386
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 387
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 388
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 389
Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 390
Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 391
Novartis Prices Public Offering of 0.75% Notes Due 2021 for USD756.5 Million 392
Novartis Prices Public Offering of 1.625% Notes Due 2026 for USD756.5 Million 393
Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 394
Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 395
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 396
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 397
Novartis May Sell Dermatology Generics Business 398
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 399
Torrent Pharma Acquires Two Brands of Women Healthcare Segment from Novartis 400
Lotus Pharma Acquires Osteoporosis from Novartis 401
Novartis May Sell Respiratory Drugs Portfolio 402
Sun Pharma to Acquire Odomzo from Novartis 404
Novartis May Sell Ritalin, Clozaril and Exelon Drugs 405
Upsher-Smith Labs Acquires 20 US Generic Products from Sandoz 406
Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 407
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 408
Sun Pharma Acquires 14 Brands from Novartis for USD293 Million 409
CSL Acquires Influenza Vaccines Business of Novartis for USD275 Million 410
Mereo BioPharma Acquires Clinical Assets from Novartis 414
Merus Labs Acquires Rights to Salagen and Estraderm MX from Novartis Pharma for USD30 Million 415
Arrowhead Research Acquires RNAi R&D Portfolio from Novartis for USD35 Million 416
GlaxoSmithKline Acquires Consumer Healthcare Pharma Business of Novartis 417
Array BioPharma Acquires Encorafenib from Novartis Pharma 419
GlaxoSmithKline Acquires Vaccines Business of Novartis for up to USD7.1 Billion 421
Aspen Pharmacare to Acquire Rights to Mono-Embolex from Novartis 423
China Medical System Acquires Rights to Lamisil and Parlodel from Novartis 424
Tribute Pharma Acquires Canadian Rights to Fiorinal, Fiorinal C, Visken and Viskazide from Novartis 426
Merus Labs Acquires Sintrom from Novartis 427
Novartis India to Sell Its OTC Division to GlaxoSmithKline Consumer 428
Lansen Pharma Acquires Sicorten Plus From Novartis For US$9.5 Million 429
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 430
Alliance Pharma Acquires Rights To Lypsyl From Novartis For US$3 Million 432
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 433
Alliance Pharma Acquires Overseas Rights To Syntometrine From Novartis For US$11.5 Million 435
Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For US$33 Million 436
Validus Pharma And Wood Creek Capital Management Acquire Six Product Lines From Novartis Pharma 437
Merus Labs Completes Acquisition Of Prescription Medicine Product From Novartis 439
Meda Completes Acquisition Of Global Rights To Elidel From Novartis For US$420 Million 440
Laboratoires Thea Acquires Rights To 19 Ophthalmic Products From Novartis 442
Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion 444
United Therapeutics May Sell Itself 445
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 446
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 447
Novartis May Acquire Genfit 449
Novartis Acquires Encore Vision 450
Novartis Acquires Ziarco Group 451
Novartis May Acquire Intercept Pharma 452
Novartis Pharma Acquires Selexys Pharma for up to USD665 Million 453
Novartis May Acquire Amneal Pharma 455
International Chemical Investors Acquires Sandoz Industrial Products from Novartis 456
Novartis Acquired Admune Therapeutics 457
Novartis to Acquire Additional 2.5% Stake in Gamida Cell for USD15 Million 458
Novartis Acquires Spinifex Pharma 459
Novartis Pharma to Acquire 15% Stake in Gamida Cell for USD35 Million 460
Novartis Acquires CoStim Pharma 461
Novartis To Acquire Sideris Pharma For Up To US$300 Million 463
GlaxoSmithKline Acquires Okairos For US$325 Million 464
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 466
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 468
Novartis Completes Acquisition Of Fougera Pharma, Dermatology Company, For US$1.5 Billion 470
Takeda Completes Acquisition Of Intellikine For US$310 Million 472
Valeant Pharma International Acquires Additional 6.33% Stake In Sanitas For US$27.8 Million 474
Ever Pharma Acquires Jenahexal Pharma From Hexal 476
Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 477
Novartis Completes Acquisition Of 85% Stake In Zhejiang Tianyuan 479
Novartis Completes Acquisition Of Genoptix 480
Novartis AG, Key Competitors 482
Novartis AG, Key Employees 483
Novartis AG, Subsidiaries 484